Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

MPN Congress 2022 and Polycythemia Vera View overview page

Fibrotic progression of ET and PV: clinical and biological considerations
Raajit Rampal • 24 Nov 2022
Dynamic personalized thrombosis prediction in polycythemia vera
Ghaith Abu-Zeinah • 24 Nov 2022
Polycythemia vera: myths, mechanisms, and management
Jerry Spivak • 24 Nov 2022
Factoring in symptoms into managing MPNs
Ruben Mesa • 24 Nov 2022
Promising new MPN treatments
John Mascarenhas • 24 Nov 2022
A paradigm shift in the diagnosis and treatment of MPNs
Hans Hasselbalch • 24 Nov 2022
The MPN microenvironment
Angela Fleischman • 24 Nov 2022
Leveraging inflammatory cytokine signaling for therapeutic benefit in MPNs
Stephen Oh • 24 Nov 2022
Are megakaryocytes the root of MPN evils?
Joseph Scandura • 24 Nov 2022
Oxygen-sensing mechanisms and erythrocytosis
Josef Prchal • 24 Nov 2022
Pursuing monoclonal antibodies for MPNs: targeting mutant calreticulin
Ann Mullally • 24 Nov 2022
JAK2V617F VAF: clinical significance and applications in polycythemia vera
Alison Moliterno • 24 Nov 2022
1:35
Novel mutations in PV & the importance of understanding their role in disease initiation
Josef Prchal • 24 Oct 2022
7:03
JAK2 V617F VAF as a diagnostic and prognostic marker for polycythemia vera and thrombosis risk
Alison Moliterno • 31 Oct 2022
3:19
Targeting JAK2 V617F VAF in polycythemia vera & the efficacy of ropeginterferon alfa-2b
Alison Moliterno • 31 Oct 2022
2:03
A study of dizygotic twins with JAK2-positive MPNs
Josef Prchal • 24 Oct 2022
The content of VJHemOnc is intended for healthcare professionals